POSC49 The Cost-Effectiveness of Brentuximab Vedotin in Frontline Systemic Anaplastic Large Cell Lymphoma in France
Abstract
Authors
O Chaker A Nucit O Salvignol AC Thoren H Cranmer C Coulibaly J Chevalier I Borget
O Chaker A Nucit O Salvignol AC Thoren H Cranmer C Coulibaly J Chevalier I Borget
ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now